Last data update: Jun 20, 2025. (Total: 49421 publications since 2009)
Records 1-8 (of 8 Records) |
Query Trace: Wielgosz K[original query] |
---|
Prevalence of Olfactory Dysfunction among Postpartum Women and Impact of SARS-CoV-2 Infection During Pregnancy
Jacobson PT , Arduin E , Hussain M , Kyle MH , Bruno A , Powers E , Varner M , Mourad M , Tita AT , Battarbee AN , Morrill T , Reichle L , Newes-Adeyi G , Mennella JA , Wielgosz K , Gilboa SM , Stockwell MS , Dawood FS , Dumitriu D , Overdevest JB . Chem Senses 2025 ![]() Olfactory dysfunction resulting from COVID-19 has imparted a lasting impact on olfaction among the general public, including pregnant women contracting SARS-CoV-2 infection. While olfactory dysfunction can impact physical, mental, and psychosocial well-being, there has been little research on olfaction during pregnancy and postpartum, nor the impact of SARS-CoV-2 infection on olfaction while pregnant. Therefore, the primary study aims are to evaluate olfaction in the postpartum period and determine the impact of antecedent SARS-CoV-2 infection. We recruited two cohorts of postpartum women, those with a history of SARS-CoV-2 infection before or during pregnancy (COVID cohort; n = 109) and those without (non-COVID cohort; n = 226), and evaluated their olfaction during the postpartum period by administering the University of Pennsylvania Smell Identification Test. Participants were queried about demographics, past SARS-CoV-2 infections, self-reported sense of smell (both in overall ability to smell and for the presence of qualitative smell issues such as parosmia and phantosmia), and perceived cause of smell loss, if any. We found significantly fewer postpartum women with normosmia capabilities in both COVID (27%) and non-COVID (46%) cohorts compared to normative data for aged-matched (30-39 years) women (83%). Women in the non-COVID cohort had significantly higher UPSIT scores and mean subjective olfaction ratings than those in the COVID cohort (95% CI [0.77,2.41] and 95% CI [-0.83,7.34], respectively). This study reflects the largest published cohort of postpartum women evaluated for olfactory function with standardized psychophysical testing. Our findings suggest both postpartum and SARS-CoV-2 infection are associated with diminished smell function. |
Interim estimates of 2024-2025 seasonal influenza vaccine effectiveness - four vaccine effectiveness networks, United States, October 2024-February 2025
Frutos AM , Cleary S , Reeves EL , Ahmad HM , Price AM , Self WH , Zhu Y , Safdar B , Peltan ID , Gibbs KW , Exline MC , Lauring AS , Ball SW , DeSilva M , Tartof SY , Dascomb K , Irving SA , Klein NP , Dixon BE , Ong TC , Vaughn IA , House SL , Faryar KA , Nowalk MP , Gaglani M , Wernli KJ , Murugan V , Williams OL , Selvarangan R , Weinberg GA , Staat MA , Halasa NB , Sahni LC , Michaels MG , Englund JA , Kirby MK , Surie D , Dawood FS , Clopper BR , Moline HL , Link-Gelles R , Payne AB , Harker E , Wielgosz K , Weber ZA , Yang DH , Lewis NM , DeCuir J , Olson SM , Chung JR , Flannery B , Grohskopf LA , Reed C , Garg S , Ellington S . MMWR Morb Mortal Wkly Rep 2025 74 (6) 83-90 Annual influenza vaccination is recommended for all persons aged ≥6 months in the United States. Interim influenza vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits and hospitalizations from four VE networks during the 2024-25 influenza season (October 2024-February 2025). Among children and adolescents aged <18 years, VE against any influenza was 32%, 59%, and 60% in the outpatient setting in three networks, and against influenza-associated hospitalization was 63% and 78% in two networks. Among adults aged ≥18 years, VE in the outpatient setting was 36% and 54% in two networks and was 41% and 55% against hospitalization in two networks. Preliminary estimates indicate that receipt of the 2024-2025 influenza vaccine reduced the likelihood of medically attended influenza and influenza-associated hospitalization. CDC recommends annual receipt of an age-appropriate influenza vaccine by all eligible persons aged ≥6 months as long as influenza viruses continue to circulate locally. |
Relative effectiveness and immunogenicity of quadrivalent recombinant influenza vaccine versus egg-based inactivated influenza vaccine among adults aged 18-64 years: Results and experience from a randomized, double-blind trial
Grant L , Whitaker JA , Yoon SK , Lutrick K , Bhargava S , Brown CP , Zaragoza E , Fink RV , Meece J , Wielgosz K , El Sahly H , Hegmann KT , Lowe AA , Southworth A , Tatum T , Ball SW , Levine MZ , Thiese MS , Battan-Wraith S , Barnes J , Phillips AL , Fry AM , Dawood FS . Open Forum Infect Dis 2024 11 (10) ofae559 BACKGROUND: Immunogenicity studies suggest that recombinant influenza vaccine (RIV) may provide better protection against influenza than standard-dose inactivated influenza vaccines (SD IIV). This randomized trial evaluated the relative vaccine effectiveness (VE) and immunogenicity of RIV versus SD IIV in frontline workers and students aged 18-64 years. METHODS: Participants were randomized to receive RIV or SD IIV and followed for reverse-transcription polymerase chain reaction (RT-PCR)-confirmed influenza during the 2022-2023 influenza season. Sera were collected from a subset of participants before and at 1 and 6 months postvaccination and tested by hemagglutination inhibition for A/H1N1, A/H3N2, B/Yamagata, and B/Victoria and against cell-grown vaccine reference viruses for A/H1N1 and A/H3N2. RESULTS: Overall, 3988 participants were enrolled and vaccinated (25% of the trial sample size goal); RT-PCR-confirmed influenza occurred in 20 of 1963 RIV recipients and 28 of 1964 SD IIV recipients. Relative VE was 29% (95% confidence interval [CI], -26% to 60%). In the immunogenicity substudy (n = 118), the geometric mean titer ratio (GMTR) comparing RIV to SD IIV at 1 month was 2.3 (95% CI, 1.4-3.7) for cell-grown A/H1N1, 2.1 (95% CI, 1.3-3.4) for cell-grown A/H3N2, 1.1 (95% CI, .7-1.6) for B/Victoria, and 1.4 (95% CI, .9-2.0) for B/Yamagata. At 6 months, GMTRs were >1 against A/H1N1, A/H3N2, and B/Yamagata. CONCLUSIONS: Relative VE of RIV compared to SD IIV did not reach statistical significance, but RIV elicited more robust humoral immune responses to 2 of 4 vaccine viruses at 1 month and 3 of 4 viruses at 6 months after vaccination, suggesting possible improved and sustained immune protection from RIV. Clinical Trials Registration. NCT05514002. |
Association between SARS-CoV-2 infections during pregnancy and preterm live birth
Mohanty S , Tita AT , Varner M , Stockwell MS , Newes-Adeyi G , Battarbee AN , Reichle L , Morrill T , Daugherty M , Mourad M , Silverio Francisco RA , Woodworth K , Wielgosz K , Galang R , Maniatis P , Semenova V , Dawood FS . Influenza Other Respir Viruses 2023 17 (9) e13192 We examined associations between mild or asymptomatic prenatal SARS-CoV-2 infection and preterm live birth in a prospective cohort study. During August 2020-October 2021, pregnant persons were followed with systematic surveillance for RT-PCR or serologically confirmed SARS-CoV-2 infection until pregnancy end. The association between prenatal SARS-CoV-2 infection and preterm birth was assessed using Cox proportional-hazards regression. Among 954 pregnant persons with a live birth, 185 (19%) had prenatal SARS-CoV-2 infection and 123 (13%) had preterm birth. The adjusted hazard ratio for the association between SARS-CoV-2 infection and preterm birth was 1.28 (95% confidence interval 0.82-1.99, p = 0.28), although results did not reach statistical significance. |
Neutralizing antibody responses to messenger RNA coronavirus disease 2019 vaccines versus severe acute respiratory syndrome coronavirus 2 infection among pregnant women and vaccine-induced antibody transfer to infants
Dawood FS , Tita A , Stockwell MS , Newes-Adeyi G , Wielgosz K , Gyamfi-Bannerman C , Battarbee A , Reichle L , Thornburg N , Ellington S , Galang RR , Vorwaller K , Vargas CY , Morrill T , Parks M , Powers E , Gibson M , Varner M . Open Forum Infect Dis 2023 10 (5) ofad204 BACKGROUND: Early coronavirus disease 2019 (COVID-19) vaccine trials excluded pregnant women, resulting in limited data about immunogenicity and maternal-fetal antibody transfer, particularly by gestational timing of vaccination. METHODS: In this multicenter observational immunogenicity study, pregnant and nonpregnant women receiving COVID-19 vaccines were prospectively enrolled. Participants had sera collected before vaccination, at 14-28 days after each vaccine dose, at delivery (umbilical cord and peripheral), and from their infants at 3 and 6 months. Geometric mean titers (GMTs) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ID(50) neutralizing antibody (nAb) against D614G-like viruses were compared by participant characteristics. RESULTS: Overall, 23 nonpregnant and 85 pregnant participants (trimester of first vaccine dose: 10 first, 47 second, 28 third) were enrolled. Ninety-three percent (76/82 with blood samples) of pregnant participants had detectable SARS-CoV-2 nAb after 2 vaccine doses, but GMTs (95% confidence intervals) were lower in pregnant participants than nonpregnant participants (1722 [1136-2612] vs 4419 [2012-9703]; P = .04). By 3 and 6 months, 28% and 74% of infants, respectively, of vaccinated participants had no detectable nAb to D614G-like viruses. Among the 71 pregnant participants without detectable nAb before vaccination, cord blood GMTs at delivery were 5-fold higher among participants vaccinated during the third versus first trimester, and cord blood nAb titers appeared inversely correlated with weeks since first vaccine dose (R(2) = 0.06, P = .06). CONCLUSIONS: Though most pregnant women develop nAb after 2 doses of mRNA COVID-19 vaccines, this analysis suggests that infant protection from maternal vaccination varies by gestational timing of vaccination and wanes. Additional prevention strategies such as caregiver vaccination may warrant consideration to optimize infant protection. |
Agreement Between Pregnant Individuals' Self-Report of Coronavirus Disease 2019 (COVID-19) Vaccination and Medical Record Documentation.
Wielgosz K , Dawood FS , Stockwell MS , Varner M , Newes-Adeyi G , Ellington S , Vargas C , Bruno AM , Powers E , Morrill T , Reichle L , Battarbee AN , Tita AT . Obstet Gynecol 2022 140 (6) 989-992 For public health research such as vaccine uptake or effectiveness assessments, self-reported coronavirus disease 2019 (COVID-19) vaccination status may be a more efficient measure than verifying vaccination status from medical records if agreement between sources is high. We assessed agreement between self-reported and medical record-documented COVID-19 vaccination status among pregnant individuals followed in a cohort during August 2020-October 2021. At end of pregnancy, participants completed questionnaires about COVID-19 vaccine receipt during pregnancy; staff verified vaccination status using medical records. Agreement was assessed between self-reported and medical record vaccination status using Cohen's kappa. There was high agreement between self-reported and medical record vaccination status (Kappa coefficient=0.94, 95% CI 0.91-0.98), suggesting that self-report may be acceptable for ascertaining COVID-19 vaccination status during pregnancy. |
Medically Attended Influenza During Pregnancy in the 2019-2020 and 2020-2021 Influenza Seasons.
Irving SA , Shuster E , Henderson JT , Li DK , Ferber J , Odouli R , Munoz FM , Nicholson E , Hadden L , Juergens M , Newes-Adeyi G , Reichle L , Arriola CS , Dawood FS , Daugherty M , Wielgosz K , Naleway AL . Obstet Gynecol 2022 140 (5) 874-877 Influenza testing and case-confirmation rates in pregnant populations have not been reported during the coronavirus disease 2019 (COVID-19) pandemic. Using electronic medical record data from a cohort of nearly 20,000 pregnancies in the United States, this retrospective cohort study examines the frequency of acute respiratory or febrile illness encounters, influenza testing, and influenza positivity during the 2020-2021 influenza season, which occurred during the COVID-19 pandemic, compared with the 2019-2020 influenza season, which largely did not. The ratios of influenza tests to acute respiratory or febrile illness visits were similar in the 2019-2020 and 2020-2021 influenza seasons (approximately 1:8 and 1:9, respectively) but were low and varied by study site. Although influenza testing in pregnant patients continued in the 2020-2021 season, when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulation was widespread in the United States, no cases of influenza were identified in our study cohort. |
Shrinking the malaria map: progress and prospects
Feachem RG , Phillips AA , Hwang J , Cotter C , Wielgosz B , Greenwood BM , Sabot O , Rodriguez MH , Abeyasinghe RR , Ghebreyesus TA , Snow RW . Lancet 2010 376 (9752) 1566-78 In the past 150 years, roughly half of the countries in the world eliminated malaria. Nowadays, there are 99 endemic countries-67 are controlling malaria and 32 are pursuing an elimination strategy. This four-part Series presents evidence about the technical, operational, and financial dimensions of malaria elimination. The first paper in this Series reviews definitions of elimination and the state that precedes it: controlled low-endemic malaria. Feasibility assessments are described as a crucial step for a country transitioning from controlled low-endemic malaria to elimination. Characteristics of the 32 malaria-eliminating countries are presented, and contrasted with countries that pursued elimination in the past. Challenges and risks of elimination are presented, including Plasmodium vivax, resistance in the parasite and mosquito populations, and potential resurgence if investment and vigilance decrease. The benefits of elimination are outlined, specifically elimination as a regional and global public good. Priorities for the next decade are described. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Jun 20, 2025
- Content source:
- Powered by CDC PHGKB Infrastructure